PIB TrackerIndia clears its first dengue vaccine — Takeda's Qdenga, for ages 4 to 60
The drug regulator CDSCO granted marketing authorisation for Qdenga, a tetravalent live-attenuated dengue vaccine (made by Takeda), for preventing dengue in people aged 4-60 — India's first-ever dengue vaccine, already WHO-prequalified and approved in dozens of countries.
What happened
- The drug regulator CDSCO granted marketing authorisation for Qdenga, India's first dengue vaccine.
- It is a tetravalent, live-attenuated vaccine (made by Takeda, imported) for ages 4-60.
- It protects against all four dengue serotypes, given as two doses three months apart, regardless of prior exposure.
- It is WHO-prequalified and approved in around 42 countries, with ~61% efficacy vs dengue and ~84% vs hospitalisation.
- India's indigenous candidate, DengiAll (Panacea Biotec), is still in final-stage trials.
For Prelims
- CDSCO: The Central Drugs Standard Control Organisation — India's national drug regulator (headed by the DCGI), which approves drugs and vaccines under the Drugs and Cosmetics Act.
- Qdenga (TAK-003): A tetravalent live-attenuated dengue vaccine (Takeda) — protects against all four serotypes (DENV 1-4); two doses, three months apart.
- Dengue: A viral disease spread by the Aedes aegypti mosquito; a second infection with a different serotype can be more severe.
- WHO prequalification: A WHO quality/safety/efficacy assessment that lets UN agencies procure a vaccine; Qdenga is the second dengue vaccine prequalified.
- Indigenous candidate: DengiAll (Panacea Biotec, with ICMR) — a single-dose Indian candidate in Phase-3 trials.
- Prevention mix: Vaccination complements vector control (source reduction, anti-larval measures) in dengue prevention.
For UPSC: A public-health and biotech item — India's first dengue vaccine approval and the regulatory pathway. Use it for the CDSCO/DCGI and drug regulation, vaccine science (tetravalent/live-attenuated), vector-borne diseases and India's dengue burden, and indigenous vaccine development (DengiAll).
What it is NOT: This is a regulatory marketing approval of an imported vaccine (Takeda's Qdenga), not the launch of an indigenous vaccine or a national immunisation programme. Approval enables availability; roll-out/programmatic use is a separate decision.
For Mains
Syllabus: GS2.13 · GS3.13 · Linkage L2
Anchor
A new tool against dengue — the first vaccine approval strengthening prevention of a rising vector-borne disease.
Substantiation (data)
CDSCO approved Qdenga (Takeda), India's first dengue vaccine, for ages 4-60; tetravalent live-attenuated, two doses; WHO-prequalified, approved in ~42 countries; indigenous DengiAll in Phase-3.
Exemplification
Tetravalent protection across all four serotypes without pre-vaccination testing; the CDSCO evaluation under the Drugs and Cosmetics Act.
Problematisation
Access, cost and programmatic prioritisation; the need to pair vaccination with vector control; awaiting indigenous options.
Way-forward
Decide on programmatic use for high-burden areas, advance indigenous vaccines (DengiAll), and sustain vector control and surveillance.
Position
Regulatory approval of an effective vaccine, combined with vector control and indigenous R&D, can cut the dengue burden.
Deploys into: Science & technology — health/HR + bio/vaccines (GS2.13, GS3.13) · the CDSCO/DCGI and drug regulation, dengue and vector-borne diseases, and vaccine development (Qdenga; indigenous DengiAll).
Ministry of Health and Family Welfare · 2026-07-21 · PRID 2286883 · PIB source ↗